Skip to main content

Mouse CCL17/TARC Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF529

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF529

Key Product Details

Species Reactivity

Validated:

Mouse

Cited:

Human, Mouse

Applications

Validated:

ELISA Detection (Matched Antibody Pair), Western Blot

Cited:

ELISA Development, Luminex Development

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

E. coli-derived recombinant mouse CCL17/TARC
Ala24-Pro93
Accession # Q9WUZ6

Specificity

Detects mouse CCL17/TARC in ELISAs and Western blots. In sandwich immunoassays, less than 0.1% cross-reactivity with recombinant human (rh) TARC, rhI-309, recombinant mouse (rm) RANTES, rmMIP-1 alpha, rmMIP-1 beta and rhMCP-1, -2, -3 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Mouse CCL17/TARC Biotinylated Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse CCL17/TARC (Catalog # 529-TR)

Mouse CCL17/TARC Sandwich Immunoassay

ELISA Detection (Matched Antibody Pair)
Recommended Concentration: 0.1-0.4 µg/mL
Use in combination with these reagents:
  • Capture Reagent: Mouse CCL17/TARC Antibody (Catalog # MAB529)
  • Standard: Recombinant Mouse CCL17/TARC Protein (Catalog # 529-TR)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 5 using BAF529 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL17/TARC

Human thymus and activation-regulated chemokine (TARC) also known as CCL17, is a novel CC chemokine identified using a signal sequence trap method. Mouse TARC was discovered as a dendritic cell (DC) specific gene by differentiation RNA display. Mouse TARC cDNA encodes a highly basic 93 amino acid (aa) residue precursor protein with a 23 aa residue putative signal peptide that is cleaved to generate the 70 aa residue mature secreted protein. Among CC chemokine family members, TARC has approximately 24‑29% amino acid sequence identity with RANTES, MIP-1 alpha, MIP-1 beta, MCP-1, MCP-2, MCP-3 and I-309. The gene for human TARC has been mapped to chromosome 16q13 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Mouse TARC is constitutively expressed in thymic DC, and at a lower level in lymph node DC in the lung. Recombinant TARC has been shown to be chemotactic for T cell lines and antigen-primed T helper cells. In humans, TARC was identified to be a specific functional ligand for CCR-4 and CCR-8, receptors that are selectively expressed on T cells.

References

  1. Imai, T. et al. (1997) J. Biol. Chem. 272:15036.
  2. Imai, T. et al. (1996) J. Biol. Chem. 271:21514.
  3. Nomiyama, H. et al. (1997) Genomics 40:211.
  4. Lieberam, I. et al. (1999) Eur. J. Immunol. 29:2684.

Alternate Names

ABCD-2, SCYA17, TARC

Entrez Gene IDs

6361 (Human); 20295 (Mouse)

Gene Symbol

CCL17

UniProt

Additional CCL17/TARC Products

Product Documents for Mouse CCL17/TARC Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Mouse CCL17/TARC Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...